SAGE Therapeutics's market cap is currently ―. The company's EPS TTM is $-9.053; its P/E ratio is -1.44; SAGE Therapeutics is scheduled to report earnings on April 25, 2024, and the estimated EPS forecast is $-1.65. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ 2.72M	$ 2.46M	$ 3.29M	$ 2.86M	$ 1.74M
Gross Profit	$ 2.72M	$ 2.47M	$ 3.29M	$ 2.86M	$ 1.55M
EBIT	$ -199.82M	$ -159.91M	$ -155.66M	$ -153.94M	$ -141.48M
EBITDA	$ -199.49M	$ -159.58M	$ -155.34M	$ -153.67M	$ -141.20M
Net Income Common Stockholders	$ -199.82M	$ -160.32M	$ -146.83M	$ -147.15M	$ -137.32M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 876.05M	$ 1.00B	$ 1.13B	$ 1.27B	$ 1.39B
Total Assets	$ 949.66M	$ 1.08B	$ 1.22B	$ 1.35B	$ 1.49B
Total Debt	$ 6.97M	$ 8.73M	$ 10.45M	$ 12.13M	$ 13.77M
Net Debt	$ -869.09M	$ -993.89M	$ -1.12B	$ -1.26B	$ -1.38B
Total Liabilities	$ 133.00M	$ 97.91M	$ 87.56M	$ 1.38B	$ 105.95M
Stockholders Equity	$ 816.66M	$ 984.38M	$ 1.13B	$ 1.28B	$ 1.38B
Cash Flow	-
Free Cash Flow	$ -136.19M	$ -131.63M	$ -153.91M	$ -127.24M	$ -119.23M
Operating Cash Flow	$ -135.87M	$ -131.52M	$ -153.68M	$ -126.95M	$ -118.86M
Investing Cash Flow	$ 160.39M	$ 45.59M	$ 194.87M	$ 89.78M	$ 110.95M
Financing Cash Flow	$ 2.77M	$ 847.00K	$ 2.67M	$ 29.00K	$ 1.23M

Currency in USD

SAGE Therapeutics Earnings and Revenue History

Income Statement >

SAGE Therapeutics Debt to Assets

Balance Sheet >

SAGE Therapeutics Cash Flow

Cash Flow >

SAGE Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing